Publications of H. Hermeking

Journal Article (35)

21.
Journal Article
Mhawech, P.; Benz, A.; Cerato, C.; Greloz, V.; Assaly, M.; Desmond, J. C.; Koeffler, H. P.; Lodygin, D.; Hermeking, H.; Herrmann, F. et al.; Schwaller, J.: Downregulation of 14-3-3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Modern Pathology 18 (3), pp. 340 - 348 (2005)
22.
Journal Article
Hermeking, H.: Extracellular 14-3-3 sigma protein: A potential mediator of epithelial-mesenchymal interactions. Journal of Investigative Dermatology 124 (1), pp. IX - X (2005)
23.
Journal Article
Lodygin, D.; Diebold, J.; Hermeking, H.: Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression. Oncogene 23 (56), pp. 9034 - 9041 (2004)
24.
Journal Article
Pawar, S. A.; Szentirmay, M. N.; Hermeking, H.; Sawadogo, M.: Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc. Oncogene 23 (36), pp. 6125 - 6135 (2004)
25.
Journal Article
Herzinger, T.; Lodygin, D.; Yazdi, A. S.; Hermeking, H.: Loss of 14-3-3S expression in basal cell carcinoma by epigenetic si-lencing via CPG-methylation. Journal of the American Academy of Dermatology 50 (3 Suppl. Suppl. S), p. P127 - P127 (2004)
26.
Journal Article
Hermeking, H.: Principles of Molecular Oncology. The Lancet Oncology 5, pp. 388 - 389 (2004)
27.
Journal Article
Hermeking, H.: The 14-3-3 cancer connection. Nature Reviews Cancer 3 (12), pp. 931 - 943 (2003)
28.
Journal Article
Lodygin, D.; Yazdi, A. S.; Sander, C. A.; Herzinger, T.; Hermeking, H.: Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22 (35), pp. 5519 - 5524 (2003)
29.
Journal Article
Hermeking, H.: Serial analysis of gene expression and cancer. Current Opinion in Oncology 15 (1), pp. 44 - 49 (2003)
30.
Journal Article
Hermeking, H.: The c-MYC oncogene as a cancer drug target. Current Cancer Drug Targets 3, pp. 163 - 175 (2003)
31.
Journal Article
Lodygin, D.; Menssen, A.; Hermeking, H.: Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. Journal of Clinical Investigation 110 (11), pp. 1717 - 1727 (2002)
32.
Journal Article
Untergasser, G.; Koch, H. B.; Menssen, A.; Hermeking, H.: Characterization of epithelial senescence by serial analysis of gene expression: Identification of genes potentially involved in prostate cancer. Cancer Research 62 (21), pp. 6255 - 6262 (2002)
33.
Journal Article
Menssen, A.; Hermeking, H.: Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes. Proceedings of the National Academy of Sciences of the United States of America 99 (9), pp. 6274 - 6279 (2002)
34.
Journal Article
Hermeking, H.: Serial analysis of gene expression and cancer. Current Opinion in Oncology 15, pp. 44 - 49 (2002)
35.
Journal Article
Lodygin, D.; Menssen, A.-; Hermeking, H.: Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. Journal of Clinical Investigation 110, pp. 1717 - 1727 (2002)

Book Chapter (1)

36.
Book Chapter
Hermeking, H.: Cancer Drug Target Identification by SAGE, LongSAGE and Digital Karyotyping. In: The Applied Oncogenomics Handbook, pp. 19 - 30 (Eds. Shimkets, R. A.; LaRochelle, W. J.). Humana Press, Cancer Target Discovery and Development-Series, Totowa/USA (2005)

Thesis - Habilitation (1)

37.
Thesis - Habilitation
Hermeking, H.: Identifizierung von Effektoren des p53 Tumorsuppressorgens und des c-MYC Onkogens sowie Untersuchungen zu epigenetischen Veränderungen und zellulärer Seneszenz in Tumoren. Habilitation, Ludwig-Maximilians-Universität, München (2006)
Go to Editor View